Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Ascrinvacumab||Phase I||Actionable||In a Phase I trial, PF-03446962 treatment was deemed safe and resulted in anti-tumor activity in patients with advanced solid tumors, demonstrating a partial response in 6.8% (3/44) and stable disease in 27.3% (12/44) (PMID: 26655846).||detail... 26655846|
|PubMed Id||Reference Title||Details|
|Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGF-beta receptor involved in tumor angiogenesis||Full reference...|
|(26655846)||A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.||Full reference...|